Cholestatic Pruritus Market Study Highlights How Industry Demand Is Evolving

The cholestatic pruritus market is anticipated to experience substantial expansion over the coming years, driven by advancements in treatment options and increasing focus on patient well-being. This report delves into the market's projected growth, leading companies, emerging trends, and key segmentation, offering a comprehensive overview of this specialized healthcare sector.

Projected Growth Trajectory of the Cholestatic Pruritus Market
The market for cholestatic pruritus is on track to reach $25.99 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.1%. This upward trend is fueled by several factors, such as the rising approval of innovative therapies, a stronger emphasis on enhancing patients' quality of life, expansion in drugs targeting liver diseases, increased funding for rare disease research, and wider adoption of personalized treatment plans. Key developments expected during the forecast period include advances in targeted anti-pruritic therapies, symptom-focused treatment methods, greater use of oral bile acid modulators, expanded research efforts in liver disease management, and more comprehensive patient-centered care approaches.

The cholestatic pruritus market size has grown strongly in recent years. It will grow from $20.22 billion in 2025 to $21.3 billion in 2026 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increasing prevalence of chronic liver diseases, limited effectiveness of traditional antihistamines, growth of hepatology specialty care, rising diagnosis of cholestatic disorders, expansion of supportive care treatments.

Download a free sample of the cholestatic pruritus market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Players Shaping the Cholestatic Pruritus Industry
The cholestatic pruritus market features several prominent companies shaping its direction, including GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Incyte Corporation, Ipsen Pharma, CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Cara Therapeutics Inc., CymaBay Therapeutics Inc., Gilead Sciences Inc., Zydus Lifesciences, Genfit SA, NGM Biopharmaceuticals Inc., Calliditas Therapeutics AB, Avior Inc, Travere Therapeutics Inc., 89bio, Hepion Pharmaceuticals, Liminal BioSciences, and ProQR Therapeutics NV.

In a notable development in September 2023, US-based Travere Therapeutics Inc. entered into a partnership with Mirum Pharmaceuticals Inc. This collaboration allows Travere to focus on its core therapeutic areas while enabling Mirum to expand and advance its portfolio of bile acid therapies aimed at rare liver diseases, including cholestatic pruritus. Mirum Pharmaceuticals specializes in developing and commercializing treatments specifically for rare liver conditions.

View the full cholestatic pruritus market report:
https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Trends Highlighting Innovation in the Cholestatic Pruritus Market
Key industry players are concentrating on creating novel oral therapies designed to effectively manage symptoms, improve patient adherence, and provide targeted relief by addressing bile salt buildup and inflammation. Oral solutions for cholestatic pruritus represent a significant advancement, offering liquid formulations that reduce bile acid accumulation and ease severe itching associated with cholestasis.

A prime example of this progress occurred in March 2024 when Mirum Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution. Indicated for patients aged five and older suffering from progressive familial intrahepatic cholestasis (PFIC), LIVMARLI is an ileal bile acid transporter inhibitor administered once daily. This medication holds breakthrough therapy status for PFIC type 2 and promises to deliver much-needed treatment options for patients experiencing cholestatic pruritus linked to rare liver disease subtypes.

Key Segmentation of the Global Cholestatic Pruritus Market
The cholestatic pruritus market is categorized in the report by the following segments:

1) Disease Type:
- Primary Biliary Cholangitis (PBC)
- Primary Sclerosing Cholangitis (PSC)
- Intrahepatic Cholestasis Of Pregnancy (ICP)
- Other Disease Types

2) Treatment Type:
- Medications
- Phototherapy
- Other Treatment Types

3) Route of Administration:
- Oral
- Topical
- Injectable

4) End-User:
- Hospitals
- Clinics
- Ambulatory Care Centers
- Homecare

Further subdivisions within disease types include:
- Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure
- Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures
- Intrahepatic Cholestasis Of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk
- Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders

This detailed segmentation enables a nuanced understanding of the market dynamics across different patient groups, treatment options, and care settings.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.